The use of leflunomide in transplantation immunology (Q41189695)

28 September 2017

1 reference

title

The use of leflunomide in transplantation immunology (English)

1 reference

28 September 2017

Waer M

1

1 reference

28 September 2017

1 September 1996

1 reference

28 September 2017

Transplant Immunology

1 reference

28 September 2017

4

1 reference

28 September 2017

3

1 reference

28 September 2017

181-185

1 reference

Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity--I. Disease modifying action on adjuvant arthritis of the rat

28 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2896%2980014-1

7 January 2021

Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2896%2980014-1

7 January 2021

Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2896%2980014-1

7 January 2021

Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2896%2980014-1

7 January 2021

Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2896%2980014-1

7 January 2021

Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2896%2980014-1

7 January 2021

Immunomodulation of proteoglycan-induced progressive polyarthritis by lefluflomide

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2896%2980014-1

7 January 2021

Leflunomide interferes with pyrimidine nucleotide biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2896%2980014-1

7 January 2021

Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2896%2980014-1

7 January 2021

Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2896%2980014-1

7 January 2021

Leflunomide, a novel immunosuppressive agent. The mechanism of inhibition of T cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2896%2980014-1

7 January 2021

A short-term combination therapy with cyclosporine and rapamycin or leflunomide induces long-term heart allograft survival in a strongly immunogenic strain combination in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2896%2980014-1

7 January 2021

The "Ly-1 B" cell subpopulation in normal immunodefective, and autoimmune mice

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2896%2980014-1

7 January 2021

Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2896%2980014-1

7 January 2021

Pharmacologically induced regression of chronic transplant rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2896%2980014-1

7 January 2021

10.1016/S0966-3274(96)80014-1

Identifiers

DOI

1 reference

28 September 2017

1 reference

PubMed ID

8893446